Shares of Anacor Pharmaceuticals (NASDAQ:ANAC) jumped 26% one day, and 30% the next, with an even bigger catalyst on the horizon. What is driving these explosive share price surges? In the video below, Fool analyst David Williamson discusses one phase 2 trial that has the markets excited, and tells us why the results from its upcoming phase 3 trial for this candidate pipeline drug could be even bigger.
David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Anacor Pharmaceuticals, Inc. Stock Jumped 58.3% in May
Here's what made the purveyor of novel ointments' share price skyrocket last month.
Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why
While complimentary to its product portfolio, Pfizer's acquisition of Anacor could take a long time to pay off for shareholders.
Here's What Pfizer's Telling Us About Biotech M&A
Pfizer's acquisition of Anacor shows M&A is alive and well for biotech companies with late-stage research programs.